Mebeverine Hydrochloride Bristol Laboratories (Mebeverine Hydrochloride)

Mebeverine Hydrochloride is a gastrointestinal antispasmodic that acts on smooth‑muscle tone in the gut.

• Irritable bowel syndrome: reduces abdominal pain, cramping and irregular bowel movements.
• Functional bowel disorders: eases spasms and improves bowel habit regularity.
• Spastic colon: diminishes colonic muscle contractions and associated discomfort.

• Mebeverine Hydrochloride acts as a direct smooth‑muscle relaxant in the gastrointestinal tract, likely by inhibiting calcium influx into smooth‑muscle cells. This reduction in intracellular calcium diminishes muscle contractility, thereby relieving spasm without significant anticholinergic activity.

Mebeverine Hydrochloride may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Dry mouth: reduced salivation.
• Headache: transient cranial discomfort.
• Dizziness: light‑headed sensation.
• Abdominal discomfort: mild pain or bloating.
• Constipation: reduced bowel frequency.

Serious or Rare Side Effects

• Allergic reactions: rash, urticaria, or angioedema.
• Severe hypotension: marked drop in blood pressure.
• Cardiac arrhythmia: irregular heart rhythm.
• Hepatotoxicity: signs of liver injury.
• Severe skin reactions: Stevens‑Johnson syndrome.
• Urinary retention: difficulty emptying the bladder.

Before initiating therapy, clinicians should consider several safety measures.

• Assess renal and hepatic function: adjust use if organ impairment is present.
• Review concomitant medications: avoid additive antispasmodic effects.
• Use with caution in the elderly: increased sensitivity to side effects.
• Avoid in patients with known hypersensitivity to mebeverine or excipients.
• Monitor for cardiac symptoms: report palpitations or fainting.
• Store at below 25°C: keep in the original pack, protect from moisture.

Mebeverine Hydrochloride can interact with other agents that affect smooth‑muscle tone or metabolism.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels.
• Other potent antispasmodics (e.g., dicyclomine): risk of excessive smooth‑muscle relaxation.

Moderate Interactions (Monitor Closely)

• Anticholinergic drugs (e.g., atropine): may enhance dry‑mouth effect.
• Antihypertensives: monitor blood pressure for additive hypotensive effect.
• Medications affecting electrolyte balance (e.g., diuretics): watch for arrhythmia risk.